Clinical Data's vilazodone succeeds in second Phase III trial
04 June 2009
Katie McQue
Clinical Data Inc has announced positive top-line data from its second pivotal Phase III trial of its novel antidepressant vilazodone in patients with major depressive disorder (MDD).
The Connecticut-based company said that it was on track to file vilazodone in the US by the end of the year....
Please Login to read the full article.
04 June 2009
Katie McQue
The Connecticut-based company said that it was on track to file vilazodone in the US by the end of the year....
Please Login to read the full article.
RELATED CONTENT
NEWS
- Major disappointment for Targacept and AstraZeneca in Phase III depression trial
- Forest to acquire Clinical Data Inc to add antidepressant Viibryd to portfolio
- Antidepressant success in Phase III cheers Forest and Pierre Fabre
- Long road ahead for Forest as Lexapro approaches abyss
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
